Osteoarthritis and Bone Disorders News

AMSTERDAM — Approximately 67% of the elevated risk for cardiovascular disease associated with patients with osteoarthritis were attributed to the use of NSAIDs, according to findings presented at the EULAR Annual Congress.

Although rates of physical activity generally increase after arthroplasty when recovery is stable, approximately one-third of patients who undergo the procedure fail to participate in physical exercise at least once per week, according to findings published in Arthritis Care and Research.

Poor sleep quality is significantly associated with decreased physical activity in patients who have or are at risk for knee osteoarthritis, according to findings published in Arthritis Care and Research.

Kitov Pharma announced that a combination of celecoxib and amlodipine besylate for treatment of patients with osteoarthritis pain and hypertension has been approved for marketing by the FDA.

New research suggests that men older than 65 years with known risk factors for fractures should be screened for osteoporosis, according to findings presented at the American Geriatrics Society annual meeting.

Physicians need to have full knowledge of their patients’ needs, preferences and priorities, as well as their pain characteristics and history, to enact personalized management plans, which should include patient education and considerations for multidisciplinary intervention, according to recommendations published by a EULAR task force.

DESTIN, Fla. — Among previously untreated patients with osteoporosis who are at high risk for fracture, proactive therapy with anabolic agents, followed by sequential monotherapy with denosumab, can minimize pharmacology exposure while maximizing benefits to bone mineral density and strength, according to findings presented at the 2018 Congress of Clinical Rheumatology.

DESTIN, Fla. —Patients with osteoporosis treated with romosozumab demonstrated substantial gains in bone mineral density and T-score increases within 1 year, with continued progress following transition to denosumab, according to findings presented at the 2018 Congress of Clinical Rheumatology.

Despite symptom relief among patients who underwent focal resurfacing for the treatment of early osteoarthritis cartilage lesions, results presented at the European Society of Sports Traumatology, Knee Surgery and Arthroscopy showed patients also had a high revision rate to arthroplasty.

Researchers from the Hospital for Special Surgery are currently enrolling patients for a 2-year pilot study to determine the effects of secukinumab on the skeleton among men and women with ankylosing spondylitis, according to a press release.